More than half of novel drug approvals were based on single studies in 2022
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticals